INTRODUCTION {#s1}
============

Niemann--Pick disease type C (NPC; OMIM 257220) is a disorder of intralysosomal cholesterol trafficking due to compound heterozygous or homozygous mutations in either *NPC1* (95%) or *NPC2* (5%), respectively ([@ROHANIZADEGANMCS002147C28]; [@ROHANIZADEGANMCS002147C5]; [@ROHANIZADEGANMCS002147C20]). *NPC1* encodes a membrane protein that has several domains homologous to other integral membrane proteins that respond to cell cholesterol content ([@ROHANIZADEGANMCS002147C3]; [@ROHANIZADEGANMCS002147C7]). NPC2 in contrast is a lysosomal glycoprotein that is secreted, although its function is poorly understood ([@ROHANIZADEGANMCS002147C20]; [@ROHANIZADEGANMCS002147C33]). NPC1 and NPC2 act in concert to facilitate the intracellular transport of LDL-derived cholesterol and lipids from the lysosomes to other sites ([@ROHANIZADEGANMCS002147C6]; [@ROHANIZADEGANMCS002147C41]). The clinical phenotype of NPC follows a continuous spectrum ranging from severe, fetal-onset to mild, adult-onset disease. The prognosis of cases with fetal-onset NPC is very poor with the majority of individuals dying from liver disease within the first months of life ([@ROHANIZADEGANMCS002147C27]). A subset of these will survive to later develop severe neurological disease. Classical childhood-onset NPC typically presents with asymptomatic hepatosplenomegaly and progressive neurological disease, whereas adult-onset NPC presents with neurological dysfunction at a slower rate of progression and/or with psychosis or other psychiatric illnesses. The rate of neurocognitive decline is variable depending on genotype, ancestry, and other yet-unidentified genetic modifiers. NPC is a panethnic disorder with an estimated incidence rate of between 1/150,000 and 1/1,000,000 live births ([@ROHANIZADEGANMCS002147C34]; [@ROHANIZADEGANMCS002147C19]; [@ROHANIZADEGANMCS002147C10]). Diagnosis of NPC is based on clinical suspicion followed by analysis of plasma oxysterol (cholestane-3β,5α,6β-triol) levels, filipin staining of fibroblasts, and molecular confirmation ([@ROHANIZADEGANMCS002147C35]). Liver biopsy may reveal lipid-laden macrophages (foam cells) and polymorphous cytoplasmic bodies on electron microscopy in skin ([@ROHANIZADEGANMCS002147C4]; [@ROHANIZADEGANMCS002147C35]).

The neonatal phenotype of NPC may be obscured by the acuity of its symptoms and missed unless evaluated with specific and sensitive biochemical and molecular tests. Next-generation sequencing--based gene panels, whole-exome sequencing (WES), and whole-genome sequencing (WGS) are powerful analytical tools for the diagnosis of rare genetic disorders including NPC ([@ROHANIZADEGANMCS002147C1]; [@ROHANIZADEGANMCS002147C37]). These tools are increasingly used in critically ill neonates to reduce time to diagnosis and to open a window for individualized therapy and management in a timely manner ([@ROHANIZADEGANMCS002147C24]). WES may be overall cost-saving when compared with traditional diagnostic strategies, in particular when used as a first-tier test ([@ROHANIZADEGANMCS002147C36]).

Here we report the utility of rWES for the diagnosis of neonatal NPC presenting with fetal hydrops and acute liver failure. The diagnosis of NPC following rWES allowed informed decision-making regarding supportive therapy and withdrawal of care, thereby alleviating the need for a costly and invasive liver transplantation.

RESULTS {#s2}
=======

Clinical Presentation and Family History {#s2a}
----------------------------------------

The male index patient was born to a 47-yr-old G5P3 mother with a history of depression and chronic anemia due to α-thalassemia trait and to a 45-yr-old healthy father. The parents are nonconsanguineous and of mixed Armenian, Iranian, and Turkish descent. The family history is otherwise noncontributory. The mother had two prior first-trimester miscarriages. The index patient was the third child for the couple following two healthy sons, who are 6 and 9 yr old, respectively. The pregnancy was complicated by fetal hydrops including pericardial effusions and ascites, which was first identified at 29 wk of gestation. Chorionic villous sampling at 16 wk of gestation because of advanced maternal age revealed a normal 46 XY karyotype. He was delivered by emergent C-section at 30 + 6 wk of gestation with Apgar scores of 2 and 5 at 1 and 5 min, respectively, a birth weight of 2300 g (81st percentile), and birth length of 52 cm (55th percentile).

Following delivery, the infant was intubated and transferred to the neonatal intensive care unit (NICU) where he underwent peritoneal drainage of fluids, exchange transfusions for hyperbilirubinemia, and transfusions of blood products and fresh frozen plasma. He developed acute signs of bowel obstruction and renal failure that were treated accordingly. On day 12 of life he was transferred to our institution for further diagnostic workup and evaluation for liver transplantation.

### Diagnostic Studies {#s2a1}

Hemoglobin electrophoresis showed 8% Barts, 8.4% A, and 83.6% F hemoglobin, consistent with α-thalassemia trait. Molecular testing was negative, whereas deletion/duplication analysis showed the common -α^20.5^ deletion, which removes HBA2 and part of HBA1, producing α^0^-thalassemia trait. The Coombs test was negative. Metabolic testing including urine organic acids, lysosomal enzyme analysis (acid β-glucosidase, sphingomyelinase, acid α-glucosidase, galactocerebrosidase, α-galactosidase, and α-[l]{.smallcaps}-iduronidase), very-long-chain fatty acids, and N- and O-glycan profiling revealed unremarkable results. A plasma acylcarnitine profile showed an isolated elevation of C5--DC, whereas urine amino acids showed multiple nonspecific elevations. The C5--DC elevation was likely explained by renal insufficiency ([@ROHANIZADEGANMCS002147C9]). Oxysterol levels were mildly elevated in dried blood: 0.97 nmol/mL (normal \< 0.63; Mayo Clinic), which was interpreted by the laboratory as not diagnostic for NPC.

A liver biopsy (light microscopy) showed diffuse hepatocellular damage with giant cell and pseudoacinar transformation, periportal ductal metaplasia, marked canalicular and cytoplasmic cholestasis, marked interstitial fibrosis (interstitial cirrhosis), and scattered foci of extramedullary hematopoiesis, but no evidence of reticuloendothelial or hepatocellular iron deposition. No lipid storage was noted. Cytomegalovirus and Epstein--Barr virus stains were negative, and MDR3 and BSEP immunohistochemical staining showed normal bicanalicular activity. Electron microscopy identified ultrastructural changes suggestive of a congenital storage disease. Hepatocytes with glycogen accumulation and dilated mitochondria with fractured cristae and proliferation of the smooth endoplasmic reticulum were seen together with numerous lamellar deposits within lysosomal spaces.

Genomic Analyses {#s2b}
----------------

Rapid WES with a turnaround of 10 business days was run as part of the diagnostic workup (XomeExpress, GeneDx Laboratories Inc.). Mitochondrial DNA sequencing including deletion/duplication testing was done in parallel with an approximate turnaround time of 35 business days. Coverage information for rWES is provided in [Table 1](#ROHANIZADEGANMCS002147TB1){ref-type="table"}. rWES revealed two heterozygous variants in *NPC1*: a maternally inherited, previously reported likely pathogenic variant in exon 18, c.2728 G\>A (p.G910S) (NM_000271.4) ([@ROHANIZADEGANMCS002147C32]) and a paternally inherited, likely pathogenic variant in exon 9, c.1547 G\>A (p.C516Y) (NM_000271.4) ([Table 2](#ROHANIZADEGANMCS002147TB2){ref-type="table"}). The latter variant is not listed in the Human Genome Mutation Database (<http://www.hgmd.cf.ac.uk/ac/index.php>) ([@ROHANIZADEGANMCS002147C29]), ClinVar (<http://www.ncbi.nlm.nih.gov/clinvar>) database, or ExAC (<http://exac.broadinstitute.org>) database ([@ROHANIZADEGANMCS002147C15]).

###### 

Sequencing coverage information for *NPC1* variants (c.1547G\>A and c.2728G\>A)

  Sample    Number of reads (millions)   Mean coverage   Unmapped reads (%)   Target region \>20× (%)   c.1547 G\>A (reads)   c.2728 G\>A (reads)
  --------- ---------------------------- --------------- -------------------- ------------------------- --------------------- ---------------------
  Proband   146                          175             0.2                  93                        176                   200
  Mother    172                          205             0.2                  94                        204                   229
  Father    122                          150             0.2                  93                        141                   215

###### 

Variant table

  Gene     Chr   HGVS DNA     HGVS Prot   Variant    Effect        ClinVar   Genotype
  -------- ----- ------------ ----------- ---------- ------------- --------- --------------
  *NPC1*   18q   c.1547G\>A   p.C516Y     Missense   Likely path   268186    Heterozygous
  *NPC1*   18q   c.2728G\>A   p.G910S     Missense   Likely path   268187    Heterozygous

Additional variants of unknown significance were identified in *MT-CO2* and *HBB* ([Table 3](#ROHANIZADEGANMCS002147TB3){ref-type="table"}). The m.7965T\>C variant (p.F127S) in *MT-CO2* (Complex IV, cytochrome *c* oxidase subunit II) has not been reported in Mitomap ([www.mitomap.org](www.mitomap.org)), mtDB ([www.genpat.uu.se/mtDB](www.genpat.uu.se/mtDB)), or Mitowheel (<http://mitowheel.org>). The level of heteroplasmy is ∼22% in the index patient and appears lower in the mother on Sanger sequencing (GeneDx Laboratories Inc.). The conservative amino acid substitution occurs at a nonconserved site within the protein, which makes a functional impact less likely. The maternally inherited c.208G\>A (p.G70S) variant in *HBB* (hemoglobin β) has been reported previously as the hemoglobin City of Hope (HBCH) variant. The G70S variant has an allele frequency of 0.1% in Europeans in ExAC and occurs at a position that is not conserved. There were no variants identified in *NPC2*.

###### 

Incidental findings

  Gene       Variant      Protein   Inheritance   Classification
  ---------- ------------ --------- ------------- ----------------
  *MT-CO2*   m.7965T\>C   p.F127S   Maternal      VUS
  *HBB*      c.208G\>A    p.G70S    Maternal      VUS

Mutations in their Structural Context {#s2c}
-------------------------------------

The main biological function of NPC1 is to transport lipid molecules past the glycocalyx and across the lysosomal membrane ([@ROHANIZADEGANMCS002147C14]; [@ROHANIZADEGANMCS002147C16]). The efficiency of this process is markedly increased through the initial binding of the lipid molecule to NPC2 that is present in a soluble form in the lysosomal lumen ([@ROHANIZADEGANMCS002147C11]). The three-dimensional structure of NPC1 ([Fig. 1](#ROHANIZADEGANMCS002147F1){ref-type="fig"}) shows a protein consisting of a large transmembrane unit, which includes the region formerly known as "sterol-sensing domain," and two structural luminal units ([@ROHANIZADEGANMCS002147C38]). The elements of these structural domains are not contiguous on the sequence ([Fig. 1](#ROHANIZADEGANMCS002147F1){ref-type="fig"}A). The amino-terminal regions form a lipid-binding luminal unit, distal to the membrane. Interleaved transmembrane helices and two quasi-symmetrical halves of a membrane proximal domain, the so-called NPC1-C (former NPC2-binding domain) and NPC1-I domains are located downstream from the sequence ([@ROHANIZADEGANMCS002147C38]). The two NPC1 variants of our patient, p.C516Y and p.G910S, fall within these two domains.

![NPC1 domains are color coded consistently throughout the panels---blue, cholesterol binding domain; green, NPC1-C; orange, NPC1-I, quasi symmetric partner of NPC1-C; pink, sterol sensing domain; yellow, transmembrane region. (*A*) Relative exonic distribution of previously published *NPC1* mutations. *Middle* row shows the exonic structure, whereas the height of each bar indicates the relative frequency of disease-causing mutations in each exon. Positions of the mutations described in this work are indicated with arrows. The corresponding structural domains are shown in the *bottom* row. (*B*) Structural position of the mutated amino acids Cys516 (blue spheres) and Gly910 (red spheres). A top down view of the putative lipid transport channel shows that Cys516 appears to be closer to the inner surface of the channel. The amino-terminal domain is hidden to not obstruct the view. (*C*) NPC1 protein domains and affected amino acids. NPC2 is also shown on the same scale (silver). Cholesterol molecules are shown in magenta.](RohanizadeganMCS002147_F1){#ROHANIZADEGANMCS002147F1}

NPC1-C plays a crucial role in facilitating cholesterol transfer from NPC2 onto NPC1\'s amino terminus. This domain contains four cysteine residues that are all involved in forming disulfide bonds (C468--C479, C516--C533). Disruption of a disulfide bond, as found in our patient, is expected to destabilize the entire structural domain. Accordingly, the C516--C533 pair is completely conserved across all vertebrate and insect species ([Fig. 2](#ROHANIZADEGANMCS002147F2){ref-type="fig"}). Judging by its location we may conjecture that this structural destabilization has an impact on the transport of lipids toward the transmembrane channel and on the transfer of cholesterol from NPC2 to NPC1-C for export from lysosomes ([Fig. 1](#ROHANIZADEGANMCS002147F1){ref-type="fig"}; [@ROHANIZADEGANMCS002147C8]). The neighboring R518 is directly involved in NPC2 binding.

![Cross-species conservation of the NPC1 protein sequence in relation to the two variants p.C516Y and p.G910S, respectively.](RohanizadeganMCS002147_F2){#ROHANIZADEGANMCS002147F2}

The role of p.G910S is difficult to ascertain. It belongs to a short motif (CGG) conserved throughout vertebrates ([Fig. 2](#ROHANIZADEGANMCS002147F2){ref-type="fig"}). p.G910S has been reported in association with NPC, although its impact remains obscure until the mode of interaction between NPC1, NPC2, glycocalyx, and perhaps other regulators is better understood ([@ROHANIZADEGANMCS002147C32]).

Biochemical Testing {#s2d}
-------------------

Following rWES the diagnosis of NPC1 was confirmed by analysis of oxysterol and 7-ketocholesterol plasma levels and filipin staining of cultured skin fibroblasts. Plasma oxysterol and 7-ketocholesterol levels were markedly elevated: 0.71 nmol/ml (normal \< 0.02) and \>1.00 nmol/ml (normal \< 0.05), respectively. Filipin staining of fibroblast showed massive intralysosomal accumulation of cholesterol compared with control ([Fig. 3](#ROHANIZADEGANMCS002147F3){ref-type="fig"}).

![Filipin stain of nonesterified cholesterol in fibroblasts with (*A*--*C*) and without (*D*--*F*) stimulation of LDL cholesterol uptake. (*A*,*D*) Normal control showing 100% esterification. (*B*,*E*) Known NPC 1 patient showing 1% esterification. (*C*,*F*) Index patient showing 2% esterification. Magnification, 20×.](RohanizadeganMCS002147_F3){#ROHANIZADEGANMCS002147F3}

DISCUSSION {#s3}
==========

We demonstrate the utility of rapid whole-exome sequencing for the diagnosis of prenatal-onset NPC in a young infant with acute liver failure and a history of fetal hydrops. Prenatal-onset NPC has to date only been reported in very few patients and is associated with early demise in the majority of reported cases ([@ROHANIZADEGANMCS002147C17]; [@ROHANIZADEGANMCS002147C18]; [@ROHANIZADEGANMCS002147C27]; [@ROHANIZADEGANMCS002147C30]; [@ROHANIZADEGANMCS002147C10]). The clinical course is highlighted by [@ROHANIZADEGANMCS002147C17] who reported two female infants with a history of severe fetal hydrops, hepatosplenomegaly, and acute liver failure who were born to unrelated, healthy parents. Fetal hydrops was diagnosed at 18 and 33 wk of gestational age. The diagnosis of NPC was confirmed postmortem through identification of pleomorphic lamellar cytoplasmic inclusions in neurons in one infant who died at 19 d of age and decreased intracellular esterification of exogenous cholesterol in the second infant. The second infant recovered from liver failure and was found to have mild hepatosplenomegaly and normal psychomotor development on follow-up at 17 mo of age ([@ROHANIZADEGANMCS002147C17]).

The presence of nonimmune fetal hydrops and ascites in addition to hepatosplenomegaly, liver failure, anemia, and thrombocytopenia should raise the suspicion for a wide spectrum of disorders including NPC that may be indistinguishable from each other clinically ([@ROHANIZADEGANMCS002147C27]). Consequently, the initial diagnostic approach needs to be broad and include analysis of disease-specific enzymes and biomarker in addition to histochemistry and electron microscopy of affected liver tissue ([@ROHANIZADEGANMCS002147C21]). The correct diagnosis may nevertheless be elusive because of noninformative results, as demonstrated in our case where oxysterol levels in dried blood were within the borderline range and liver biopsy did not reveal changes typically observed in NPC, although there was evidence of lamellar inclusion bodies in lysosomes on electron microscopy ([@ROHANIZADEGANMCS002147C35]).

The advent of next-generation sequencing has moved molecular testing from a second- or third-tier confirmatory to a first-tier diagnostic tool realizing its limitations ([@ROHANIZADEGANMCS002147C37]). WES and WGS with a rapid turnaround time are playing an increasingly important role for the diagnosis of critically ill infants and children ([@ROHANIZADEGANMCS002147C25]). A timely diagnosis is critical to preserve optimal health outcomes, most importantly when disease-specific therapies (enzyme replacement, transplantation, or others) are available ([@ROHANIZADEGANMCS002147C26]). As our patient was listed for liver transplantation, rWES was done, which revealed two likely pathogenic variants in *NPC1*, whose functional relevance was confirmed through analysis of oxysterol levels in plasma and cholesterol accumulation in fibroblast through filipin stain. Although it was impossible to conduct an in-depth health economic assessment, it is obvious that the direct and indirect costs for a pediatric liver transplantation far exceed those for rWES.

We cannot exclude an additional effect on the clinical course through the missense variant that was identified in *MT-CO2* (22% heteroplasmy) by mitochondrial DNA sequencing. The conservative amino acid substitution occurs at a nonconserved site within MT-CO2, which makes a functional impact less likely. Deficiency of cytochrome *c* oxidase (COX) results in a heterogeneous spectrum of neurodevelopmental phenotypes of different severity and age of onset. To the best of our knowledge acute liver failure and fetal hydrops have not been reported in any case with confirmed COX deficiency. In contrast, our patient did not exhibit severe lactic acidosis, which is typically associated with COX deficiency ([@ROHANIZADEGANMCS002147C39]).

Our case highlights the utility of rWES in an acute clinical setting for several domains of precision medicine including (1) diagnosis, (2) prognosis and outcome, (3) management and therapy, and (4) utilization of resources. The diagnosis of atypical presentations of otherwise well-known conditions may be delayed without WES, particularly when initial diagnostic testing is noninformative.

METHODS {#s4}
=======

Whole-Exome Sequencing {#s4a}
----------------------

Exome sequencing at GeneDx was performed on exon targets isolated by capture with the Clinical Research Exome kit (Agilent Technologies) using Illumina HiSeq 2500 2×100 bp. The other sequencing technology and variant interpretation protocol has been previously described ([@ROHANIZADEGANMCS002147C31]). The general assertion criteria for variant classification are publicly available on the GeneDx ClinVar submission page (<http://www.ncbi.nlm.nih.gov/clinvar/submitters/26957/>).

Protein Structure {#s4b}
-----------------

Structures of NPC1 ([@ROHANIZADEGANMCS002147C38]; PDB identifier 3jd8) and NPC2 ([@ROHANIZADEGANMCS002147C40]; PDB identifier 2hka) were downloaded from the Protein Data Bank (PDB, [@ROHANIZADEGANMCS002147C2]; <http://www.rcsb.org>). The sequence alignment for vertebrates ([@ROHANIZADEGANMCS002147C12]; <http://exolocator.eopsf.org>) was extended to include insects from the RefSeq database ([@ROHANIZADEGANMCS002147C22]; <https://www.ncbi.nlm.nih.gov/refseq/>).

Skin Biopsy and Cell Culture {#s4c}
----------------------------

In brief, a 3-mm punch biopsy was done on the outer right thigh under sterile conditions following subcutaneous local anesthesia under sterile conditions. The biopsy material was transferred to sterile DMEM supplemented with 10% fetal bovine serum (Life Technologies Inc.) and stored at room temperature until the following day. Fat tissue was removed from the biopsy, which was then cut into smaller pieces and divided between T25 flasks containing sterile DMEM 10% fetal bovine serum. T25 flasks were incubated at 37°C and 5% CO~2~ until confluency. Skin fibroblasts were harvested and re-plated into T75 flasks for subsequent filipin staining.

Filipin Stain {#s4d}
-------------

The formation of (3)H-cholesterol oleate is measured against cells that are fed only (3)H-oleic acid without low-density lipoprotein. The formed (3)H-cholesterol oleate is separated from (3)H-oleic acid and its other esterified forms by thin-layer chromatography (TLC). The areas on the TLC plates corresponding to the cholesterol oleate markers are then scraped and counted on a liquid scintillation counter. Lowry proteins are done on the cell pellet to normalize the assay roughly to cell numbers. Filipin staining for cholesterol is performed on all specimens with low values ([@ROHANIZADEGANMCS002147C13]; [@ROHANIZADEGANMCS002147C23]).

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

Our patient consent does not permit patient sequence data to be uploaded to a data repository. The *NPC1* variants reported have been deposited in the ClinVar (<http://www.ncbi.nlm.nih.gov/clinvar/>) database with accession numbers SCV000328675.3 (c.2728G\>A (p.Gly910Ser) and SCV000328674.3 (c.1547G\>A (p.Cys516Tyr), and the *HBB* (c.208G\>A(p.G70S)) variant can be found under accession number SCV000599992. The *MT-CO2* m.7965T\>C (p.F127S) variant has been submitted to ClinVar under accession number SCV000599993 and MSeqDR under accession number MSCV_0000006.
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